Autolus Therapeutics plc stock is soaring after the firm secured one of the largest-ever private financings of a UK biotech, and the largest from a single source, to fund the final stages of development of its next-generation blood cancer CAR-T therapy obecabtagene autoleucel (obe-cel).
Autolus On The Rise After Big Backing From Blackstone
Private Equity Group Investing Up To $250m
The cash injection comes as a potentially pivotal trial of Autolus's next-generation leukemia CAR-T therapy continues to enrol ahead of a readout in 2022.
